Peking University: Carcinoma trials

The registry lists 26 Carcinoma studies with Peking University as lead sponsor. 2 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 4Phase 2 18Phase 3 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell CarcinomaRecruitingNCT06690476Early Phase 1
• Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06684600Phase 2
• Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT05386056Phase 2
• JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard TherapyStatus unknownNCT05164848Phase 1
• Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal CancerStatus unknownNCT05030246Phase 2
• Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular CarcinomaStatus unknownNCT04973098Phase 1
• The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04937673Phase 2
• Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR AmplificationStatus unknownNCT04880811Phase 2
• Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine CarcinomaCompletedNCT04705519Phase 2
• Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence AlgorithmStatus unknownNCT04695015
• Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine CarcinomaStatus unknownNCT03992911Phase 2/3
• Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)Status unknownNCT03940976Phase 2
• Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)Status unknownNCT03833466Phase 2
• Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine CarcinomaStatus unknownNCT03279614Phase 2
• Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell CarcinomaTerminatedNCT03251417Phase 2
• Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine CarcinomaStatus unknownNCT03168607Phase 2
• Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine CarcinomaTerminatedNCT03168594Phase 2
• Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor ThrombosisCompletedNCT03009461Phase 2
• PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.WithdrawnNCT02867332Phase 1
• Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell CarcinomaCompletedNCT02645864Phase 1
• Octreotide LAR as Maintenance Treatment for Patients With NECStatus unknownNCT02409849Phase 2
• Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric CancerStatus unknownNCT02375997Phase 3
• Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell CarcinomaWithdrawnNCT02272699Phase 2/3
• Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 DissectionStatus unknownNCT01534546Phase 3
• mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the EsophagusStatus unknownNCT01486992Phase 2
• mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical TrialStatus unknownNCT01044420Phase 2